Name: Neurostimulus MAGence (MAGEG1) (G56160)

Target Name: NSMCE3

NCBI ID: G56160

NSMCE3

Name: Neurostimulus MAGence (MAGEG1)

Synonyms: NSMCE3, Magence, Stimulus MAGence

IUPAC Nomenclature: N/A

Chemical Structure:

MAGEG1 is a protein that belongs to the family of neuropeptides, which are a type of signaling molecule in the central nervous system (CNS). The protein consists of 214 amino acids and has a calculated molecular mass of 23.9 kDa.

MAGEG1 is expressed in various tissues of the brain, including the prefrontal cortex, basal ganglia, and spinal cord. It is involved in the regulation of neural circuits and is thought to play a role in the development and progression of various neurological disorders, such as Parkinson's disease, dystonia, and schizophrenia.

Due to its involvement in the central nervous system, MAGEG1 has been identified as a potential drug target. Researchers are exploring the use of drugs that can modulate MAGEG1 activity to treat neurological disorders.

Magenta (MAGEG1) is a protein that can be used as a drug target in the treatment of various neurological disorders.

Magenta is a small molecule that can interact with MAGEG1, leading to a reduction in the activity of the protein. This interaction between MAGEG1 and Magenta has been shown to improve the therapeutic effects of various drugs used in the treatment of neurological disorders.

One of the main benefits of Magenta is its ability to enhance the effects of dopamine, a neurotransmitter that is involved in the treatment of many neurological disorders. MAGEG1 has been shown to interact with dopamine receptors, leading to an increase in the activity of these receptors and a greater response to dopamine treatment.

In addition to its potential role in the treatment of neurological disorders, MAGEG1 has also been shown to have potential as a biomarker for the diagnosis of certain disorders. The Magenta protein has been shown to be expressed in the brains of individuals with certain neurological disorders, including Parkinson's disease and dystonia. This suggests that MAGEG1 may be a useful biomarker for the diagnosis and assessment of these disorders.

MAGEG1 is also a potential drug target for the treatment of psychiatric disorders, including depression and anxiety. Studies have shown that MAGEG1 is involved in the regulation of neural circuits that are involved in mood and anxiety, and that changes in MAGEG1 activity may contribute to the development of these disorders.

In conclusion, MAGEG1 is a protein that has the potential to be a drug target for the treatment of various neurological disorders, including Parkinson's disease, dystonia, and psychiatric disorders. The use of Magenta as a drug or biomarker could lead to new and more effective treatments for these disorders.

Protein Name: NSE3 Homolog, SMC5-SMC6 Complex Component

Functions: Component of the SMC5-SMC6 complex, a complex involved in repair of DNA double-strand breaks by homologous recombination (PubMed:20864041, PubMed:27427983). The complex may promote sister chromatid homologous recombination by recruiting the SMC1-SMC3 cohesin complex to double-strand breaks. The complex is required for telomere maintenance via recombination in ALT (alternative lengthening of telomeres) cell lines and mediates sumoylation of shelterin complex (telosome) components which is proposed to lead to shelterin complex disassembly in ALT-associated PML bodies (APBs). In vitro enhances ubiquitin ligase activity of NSMCE1. Proposed to act through recruitment and/or stabilization of the Ubl-conjugating enzyme (E2) at the E3:substrate complex (PubMed:20864041). May be a growth suppressor that facilitates the entry of the cell into cell cycle arrest (By similarity)

The "NSMCE3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NSMCE3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets